查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1578327

全球陣發性睡眠性血紅蛋白尿 (PNH) 治療市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

全球陣發性睡眠性血紅蛋白尿 (PNH) 治療市場需求預計將從 2023 年的 44.9 億美元增至 2032 年近 123.8 億美元，2024-2032 年研究期間複合年成長率為 11.92%。

陣發性睡眠性血紅素尿症（PNH）是一種慢性血液疾病，即主要影響血液的疾病。這是一種極為罕見的骨髓幹細胞疾病，影響全球 20,000 多人。這種疾病對男性和女性的影響相同。身體症狀可以在任何年齡開始，通常在30-40歲之間出現。 PNH 患者唯一的治療方法是異體幹細胞移植。

市場動態

一些血液和骨髓相關疾病的增加以及老年人口的增加是推動 PNH 治療市場成長的關鍵因素。除此之外，生物製劑的出現和新型療法的採用正在進一步推動市場成長。然而，與目前可用治療相關的副作用、醫療設備成本的增加，特別是幹細胞轉化所需的手術設備是抑制 PNH 市場成長的一些因素。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球陣發性睡眠性血紅蛋白尿 (PNH) 治療市場的各個細分市場進行了包容性評估。陣發性睡眠性血紅蛋白尿 (PNH) 治療產業的成長和趨勢為本研究提供了整體方法。

市場區隔

陣發性睡眠性血紅蛋白尿 (PNH) 治療市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略家確定相應產品或服務的目標人群以及即將到來的機會。

按治療類型

  • 補體抑制劑
  • 鐵療法
  • 免疫抑制劑藥物
  • 骨髓移植
  • 其他治療類型

依給藥途徑

  • 口服
  • 注射用

按年齡段

  • 兒科
  • 成人

按最終用途

  • 醫院
  • 專科診所
  • 家庭護理設置
  • 其他最終用戶
  • 區域分析

本節介紹區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的陣發性睡眠性血紅蛋白尿 (PNH) 治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。陣發性睡眠性血紅蛋白尿(PNH) 治療市場的主要參與者包括安進公司(Amgen Inc.)、Apellis Pharmaceuticals Inc.、阿斯特捷利康公司(AstraZeneca Plc)、美國國家兒童醫院(Children's National Hospital)、羅氏有限公司(F. Hoffmann-La Roche Ltd.)、紀念斯隆凱特琳癌症中心(Memorial Sloan Kettering Cancer Center)、諾華公司(Novartis AG)、輝瑞公司(Pfizer Inc.) .、Regeneron Pharmaceuticals Inc.、Teva Pharmaceuticals Industries Ltd.、UCLA Health、羅徹斯特大學醫學中心。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

  • 報告說明
    • 客觀的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 研究範圍
  • 研究方法
    • 市場研究過程
    • 市場研究方法論

第 2 章：執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章：陣發性睡眠性血紅素尿症 (PNH) 治療 - 產業分析

  • 簡介 - 市場動態
  • 市場促進因素
  • 市場限制
  • 機會
  • 產業動態
  • 波特五力分析
  • 市場吸引力分析
    • 按治療類型進行的市場吸引力分析
    • 按給藥途徑進行的市場吸引力分析
    • 按年齡層別分類的市場吸引力分析
    • 按最終用途分類的市場吸引力分析
    • 市場吸引力分析：按地區

第 4 章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料廠商清單
    • 主要原物料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直效行銷
    • 間接行銷
    • 行銷通路發展趨勢

第 5 章：全球陣發性睡眠性血紅素尿症 (PNH) 治療市場分析：依治療類型

  • 按治療類型概述
  • 按治療類型進行歷史和預測數據分析
  • 補體抑制劑
  • 鐵療法
  • 免疫抑制劑藥物
  • 骨髓移植
  • 其他治療類型

第 6 章：全球陣發性睡眠性血紅素尿症 (PNH) 治療市場分析：依給藥途徑

  • 依給藥途徑概述
  • 按給藥途徑進行歷史和預測資料分析
  • 口服
  • 注射用

第 7 章：全球陣發性睡眠性血紅蛋白尿 (PNH) 治療市場分析：按年齡層分類

  • 按年齡層別概述
  • 按年齡層別進行的歷史和預測資料分析
  • 兒科
  • 成人

第 8 章：全球陣發性睡眠性血紅蛋白尿 (PNH) 治療市場分析：依最終用途分類

  • 按最終用途分類的概述
  • 按最終用途進行歷史和預測資料分析
  • 醫院
  • 專科診所
  • 家庭護理設置
  • 其他最終用戶

第 9 章：全球陣發性睡眠性血紅蛋白尿 (PNH) 治療市場分析：按地理位置

  • 區域展望
  • 介紹
  • 北美銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 北美按細分市場銷售分析
    • 北美按國家銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 歐洲按細分市場銷售分析
    • 歐洲按國家銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 亞太地區按細分市場銷售分析
    • 亞太地區按國家銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳洲銷售分析
    • 東南亞銷售分析
    • 亞太地區其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 拉丁美洲按細分市場銷售分析
    • 拉丁美洲按國家銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 中東和非洲按細分市場銷售分析
    • 中東和非洲按國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東其他地區和非洲銷售分析

第 10 章：陣發性睡眠性血紅素尿症 (PNH) 治療公司的競爭格局

  • 陣發性睡眠性血紅素尿症 (PNH) 治療市場競爭
  • 夥伴關係/協作/協議
  • 併購
  • 新產品發布
  • 其他發展

第 11 章：公司簡介

  • 頂級公司市佔率分析
  • 市場集中度
  • Amgen Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Apellis Pharmaceuticals Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • AstraZeneca Plc
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Children'S National Hospital
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • F. Hoffmann-La Roche Ltd.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Memorial Sloan Kettering Cancer Center
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Novartis AG
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Pfizer Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Regeneron Pharmaceuticals Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Teva Pharmaceuticals Industries Ltd.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • UCLA Health
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • University Of Rochester Medical Center
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

Product Code: VMR11210464

The global demand for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market is presumed to reach the market size of nearly USD 12.38 Billion by 2032 from USD 4.49 Billion in 2023 with a CAGR of 11.92% under the study period 2024-2032.

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a chronic hematological disorder, i.e. disorder which primarily affects the blood. It is an ultra-rare disease of bone marrow stem cells which affects more than 20,000 people globally. This disease affects men and women equally. Physical symptoms can begin at any age, they usually develop between 30-40 years of age. The only curative therapy for PNH patients is allogeneic stem cell transplantation.

MARKET DYNAMICS

The rise in a number of blood and bone marrow related disorders and increase in geriatric population are the key factors which drive the market growth of PNH treatment market. In addition to this, the emergence of biologics and adoption of novel therapeutics are further pushing the market growth. However, adverse effects associated with currently available treatments, increase in the cost of medical equipment, specifically surgical equipment required for stem cell transformation are some factors that restrain market growth of PNH.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment. The growth and trends of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment Type

  • Complement Inhibitors
  • Iron Therapy
  • Immunosuppressant Drugs
  • Bone Marrow Transplantation
  • Other Treatment Types

By Route Of Administration

  • Oral
  • Parenteral

By Age Group

  • Pediatric
  • Adult

By End-Use

  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Other End-Users
  • Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market include Amgen Inc., Apellis Pharmaceuticals Inc., AstraZeneca Plc, Children'S National Hospital, F. Hoffmann-La Roche Ltd., Memorial Sloan Kettering Cancer Center, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Teva Pharmaceuticals Industries Ltd., UCLA Health, University Of Rochester Medical Center. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Treatment Type
    • 3.7.2 Market Attractiveness Analysis By Route Of Administration
    • 3.7.3 Market Attractiveness Analysis By Age Group
    • 3.7.4 Market Attractiveness Analysis By End-Use
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY TREATMENT TYPE

  • 5.1. Overview By Treatment Type
  • 5.2. Historical and Forecast Data Analysis By Treatment Type
  • 5.3. Complement Inhibitors Historic and Forecast Sales By Regions
  • 5.4. Iron Therapy Historic and Forecast Sales By Regions
  • 5.5. Immunosuppressant Drugs Historic and Forecast Sales By Regions
  • 5.6. Bone Marrow Transplantation Historic and Forecast Sales By Regions
  • 5.7. Other Treatment Types Historic and Forecast Sales By Regions

6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 6.1. Overview By Route Of Administration
  • 6.2. Historical and Forecast Data Analysis By Route Of Administration
  • 6.3. Oral Historic and Forecast Sales By Regions
  • 6.4. Parenteral Historic and Forecast Sales By Regions

7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY AGE GROUP

  • 7.1. Overview By Age Group
  • 7.2. Historical and Forecast Data Analysis By Age Group
  • 7.3. Pediatric Historic and Forecast Sales By Regions
  • 7.4. Adult Historic and Forecast Sales By Regions

8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY END-USE

  • 8.1. Overview By End-Use
  • 8.2. Historical and Forecast Data Analysis By End-Use
  • 8.3. Hospitals Historic and Forecast Sales By Regions
  • 8.4. Specialty Clinics Historic and Forecast Sales By Regions
  • 8.5. Homecare Settings Historic and Forecast Sales By Regions
  • 8.6. Other End-Users Historic and Forecast Sales By Regions

9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT COMPANIES

  • 10.1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Amgen Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Apellis Pharmaceuticals Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. AstraZeneca Plc
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Children'S National Hospital
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. F. Hoffmann-La Roche Ltd.
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Memorial Sloan Kettering Cancer Center
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Novartis AG
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Pfizer Inc.
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Regeneron Pharmaceuticals Inc.
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Teva Pharmaceuticals Industries Ltd.
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. UCLA Health
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. University Of Rochester Medical Center
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Treatment Type (USD MN)
  • Complement Inhibitors Market Sales By Geography (USD MN)
  • Iron Therapy Market Sales By Geography (USD MN)
  • Immunosuppressant Drugs Market Sales By Geography (USD MN)
  • Bone Marrow Transplantation Market Sales By Geography (USD MN)
  • Other Treatment Types Market Sales By Geography (USD MN)
  • Analysis By Route Of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Parenteral Market Sales By Geography (USD MN)
  • Analysis By Age Group (USD MN)
  • Pediatric Market Sales By Geography (USD MN)
  • Adult Market Sales By Geography (USD MN)
  • Analysis By End-Use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty Clinics Market Sales By Geography (USD MN)
  • Homecare Settings Market Sales By Geography (USD MN)
  • Other End-Users Market Sales By Geography (USD MN)
  • Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Treatment Type
  • Market Attractiveness Analysis By Route Of Administration
  • Market Attractiveness Analysis By Age Group
  • Market Attractiveness Analysis By End-Use
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Treatment Type (USD MN)
  • Complement Inhibitors Market Sales By Geography (USD MN)
  • Iron Therapy Market Sales By Geography (USD MN)
  • Immunosuppressant Drugs Market Sales By Geography (USD MN)
  • Bone Marrow Transplantation Market Sales By Geography (USD MN)
  • Other Treatment Types Market Sales By Geography (USD MN)
  • Global Market Analysis By Route Of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Parenteral Market Sales By Geography (USD MN)
  • Global Market Analysis By Age Group (USD MN)
  • Pediatric Market Sales By Geography (USD MN)
  • Adult Market Sales By Geography (USD MN)
  • Global Market Analysis By End-Use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty Clinics Market Sales By Geography (USD MN)
  • Homecare Settings Market Sales By Geography (USD MN)
  • Other End-Users Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.